Summary In 2018, the US National Institute on Aging and the Alzheimer's Association
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …

The global epidemic of Alzheimer disease (AD) is worsening, and no approved treatment
can revert or arrest progression of this disease. AD pathology is characterized by the …

The term “salience network” refers to a suite of brain regions whose cortical hubs are the
anterior cingulate and ventral anterior insular (ie, frontoinsular) cortices. This network, which …

Neurodegenerative diseases are the most common cause of dementia. Although their
underlying molecular pathologies have been identified, there is substantial heterogeneity in …

Amyloid-beta and tau are key molecules in the pathogenesis of Alzheimer's disease, but it
remains unclear how these proteins interact to promote disease. Here, by combining cross …

Numerous brain disorders demonstrate structural brain abnormalities, which are thought to
arise from molecular perturbations or connectome miswiring. The unique and shared …

Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to
validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite …

Resting-state functional magnetic resonance imaging (rs-fMRI) offers the opportunity to
delineate individual-specific brain networks. A major question is whether individual-specific …

It is nearly 20 years since the concept of a small-world network was first quantitatively
defined, by a combination of high clustering and short path length; and about 10 years since …

In Alzheimer's diseases (AD), tau pathology is strongly associated with cognitive decline.
Preclinical evidence suggests that tau spreads across connected neurons in an activity …